Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis.
Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis.
复制标题
microRNA-126 在癌症诊断中的潜在作用：系统评价和荟萃分析
DOI：
10.1097/md.0000000000004644
复制
发表时间：
2016-08
期刊：
影响因子：
1.6
通讯作者：
Zhang G
中科院分区：
文献类型：
--
作者：
Yan J;Ma S;Zhang Y;Yin C;Zhou X;Zhang G
癌症已成为全世界公众关注的一个主要问题，癌症的早期诊断对治疗和预后有很大的好处。一些研究调查了异常循环microRNA-126（miR-126）表达与各种癌症风险之间的关系，但结果不一致。因此，进行这项荟萃分析以评估miR-126对癌症的潜在诊断价值。我们从PubMed、Embase和Web of Science中检索了相关研究，并计算了汇总的灵敏度、特异性、阳性似然比（PLR）、阴性似然比（NLR）、诊断比值比（DOR）和汇总受试者工作特征曲线下面积（AUC），以评估miR-126对癌症检测的诊断价值。本荟萃分析共纳入7篇文献的11项研究中的745例癌症患者和749例对照。汇总估计显示，合并敏感性为68%，（95%置信区间[CI]：60-75%），特异性为76%（95% CI：65-85%），PLR为2.87（95% CI：1.96-4.21），NLR为0.42（95% CI：0.35-0.52），DOR为7（95% CI：4-11），AUC为0.77（95% CI：0.73-0.80）。此外，样本类型、癌症类型、样本大小和质量评分可能是异质性的来源。这项系统性综述和荟萃分析表明，miR-126在癌症诊断中具有很大的潜力成为非侵入性生物标志物。然而，未来需要更多设计良好的研究和更大的样本量来研究miR-126对癌症的诊断价值。
Supplemental Digital Content is available in the text Cancer has become a major public concern all over the world and early diagnosis of cancer is of great benefit for treatment and prognosis. Several studies have investigated the association between abnormal circulating microRNA-126 (miR-126) expression and the risk of various cancers, but the results are inconsistent. Therefore, this meta-analysis was carried out to assess the potential diagnostic value of miR-126 for cancer. Relevant studies were searched from PubMed, Embase, and Web of Science and we calculated the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operator characteristic curve (AUC) to assess the diagnostic value of miR-126 for cancer detection. A total of 745 cancer patients and 749 controls from 11 studies of 7 papers were included in this meta-analysis. The summary estimates revealed that the pooled sensitivity was 68% (95% confidence interval [CI]: 60–75%), the specificity was 76% (95% CI: 65–85%), the PLR was 2.87 (95% CI: 1.96–4.21), the NLR was 0.42 (95% CI: 0.35–0.52), the DOR was 7 (95% CI: 4–11), and the AUC was 0.77 (95%CI: 0.73–0.80). Moreover, the sample type, cancer type, sample size, and quality score might be sources of heterogeneity. This systematic review and meta-analysis suggests that miR-126 has great potential to be a noninvasive biomarker in the diagnosis of cancer. However, more well-designed studies with larger sample size on the diagnostic value of miR-126 for cancer are needed in the future.